KBY Biotech Indexv0.0.34
Search
← Pipeline|Gozezumab

Gozezumab

Approved
MGT-3070
By MeiraGTx
Source: Trial-derived·Trials: 1
Modality
Multispecific
MOA
C5i
Target
TIGIT
Pathway
Lipid Met
PTSDCSUBCC
Development Pipeline
Preclinical
~Apr 2016
→ ~Jul 2017
Phase 1
~Oct 2017
→ ~Jan 2019
Phase 2
~Apr 2019
→ ~Jul 2020
Phase 3
~Oct 2020
→ ~Jan 2022
NDA/BLA
~Apr 2022
→ ~Jul 2023
Approved
Oct 2023
→ May 2026
ApprovedCurrent
NCT08451646
488 pts·BCC
2023-10→2026-05·Active
488 total pts1 indication
CompletedCurrentUpcoming
Catalysts (1)
2026-05-212mo awayPh3 Readout· BCC
Trial Timeline
Q42024Q2Q3Q42025Q2Q3Q42026Q2
Approved
Active
Catalysts
Ph3 Readout
2026-05-21 · 2mo away
BCC
Active|StartCompletionToday
Trials (1)
NCTPhaseIndicationStatusNEP
NCT08451646ApprovedBCCActive488EDSS
Competitors (10)
DrugCompanyPhaseTargetMOA
ZanuderotideJohnson & JohnsonPhase 2/3TIGITGLP-1/GIP
MRK-6781Merck & CoApprovedTIGITRAS(ON)i
DSN-2247Daiichi SankyoNDA/BLAEZH2C5i
PexamavacamtenDaiichi SankyoNDA/BLATIGITCD3xCD20
BNT-5232BioNTechNDA/BLATIGITPARPi
ALN-8757AlnylamPreclinicalTIGITCFTRmod
MiritinibNeurocrinePhase 3TIGITSTINGag
UTH-9370United TherapeuticsNDA/BLATIGITPARPi
RimabrutinibMadrigal PharmaPhase 1/2GPRC5DC5i
COR-9456CorceptPreclinicalTIGITBETi